Review Article

Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection

Nishant Merchant, Calvin S. David, and Steven C. Cunningham

Department of Surgery, Saint Agnes Hospital, 900 Caton Avenue, Mailbox #207, Baltimore, MD 21229, USA

Correspondence should be addressed to Steven C. Cunningham, steven.cunningham@stagnes.org

Received 4 January 2011; Accepted 27 February 2011

Academic Editor: Pierce Chow

Copyright © 2011 Nishant Merchant et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The optimal surgical treatment of hepatocellular carcinoma on well-compensated cirrhosis is controversial. Advocates of liver transplantation cite better long-term survival, lower risk of recurrence, and the ability of transplantation to treat both the HCC and the underlying liver cirrhosis. Transplantation, however, is not universally available to all appropriate-risk candidates because of a lack of sufficient organ donors and in addition suffers from the disadvantages of requiring a more complex pre- and postoperative management associated with risks of inaccessibility, noncompliance, and late complications. Resection, by contrast, is much more easily and widely available, avoids many of those risks, is by many accounts as effective at achieving similar long-term survival, and still allows for safe, subsequent liver transplantation in cases of recurrence. Here, arguments are made in favor of resection being easier, safer, simpler, and comparably effective in the treatment of HCC relative to transplantation, and therefore being the optimal initial treatment in cases of hepatocellular carcinoma on well-compensated cirrhosis.

1. Introduction

Hepatocellular carcinoma (HCC) is the seventh most common cancer worldwide, one of the most common causes of cancer death worldwide, and its incidence is increasing [1–3]. The rate of cancer death from primary liver cancer (90% of which is HCC [4]) in the United States has increased by over 40% in recent decades [2]. Risk factors for the development of HCC include hepatitis (most commonly hepatitis B virus (HBV) or hepatitis C virus (HCV)), steatohepatitis, cirrhosis, hepatotoxins, and less commonly hereditary diseases such as hemochromatosis and alpha-1 antitrypsin deficiency. HCC uncommonly arises in healthy liver parenchyma. HBV is the most common underlying liver disease, and chronic carriers have a logarithmically increased risk of developing HCC compared to the general population [4].

2. The Debate

There is currently no consensus regarding the best surgical treatment for patients with well-compensated cirrhosis and early HCC within the Milan criteria (a single tumor <5 cm in maximum diameter, or 2-3 tumors each <3 cm, without lymphovascular invasion [5, 6]). While transplantation is clearly better for patients with severe cirrhosis and early HCC, and resection is better than transplantation for resectable but extra-Milan-criteria HCC on mild cirrhosis, on the middle ground—early HCC with mild cirrhosis—wages the debate between transplantation and resection.

3. Advantages of Liver Transplantation

The ability to treat with a single intervention not only the HCC but also the underlying oncogenic liver disease from which it arose—and by extension, from which other tumors may arise—is one of the greatest advantages of liver transplantation over resection. In high-volume centers, liver transplantation achieves this goal with acceptable morbidity and mortality (Table 1).

Furthermore, not only is liver transplantation relatively safe, but compared with resection, it has been reported to produce a longer 5-year survival and a lower rate of recurrence (Table 1). The reasons for these improved results compared to resection are difficult to discern, however, and may be related to a truly superior extirpation of gross and microscopic disease or to selection bias, especially as might...
Table 1: Series comparing RSX and LT for HCC on cirrhosis.

| First author [ref] | Year | N RSX | N LT | Mb (%) RSX | Mb (%) LT | Mt (%) RSX | Mt (%) LT | Overall 5-YS LSX | Overall 5-YS LT | Rec (%) LSX | Rec (%) LT |
|--------------------|------|-------|------|------------|----------|------------|----------|----------------|----------------|------------|------------|
| Iwatsuki wi [46]  | 1991 | 17**  | 71** | NR         | NR       | NR         | NR       | 0%             | 41%            | 50         | 43         |
| Ringewi [47]      | 1991 | 131** | 61** | NR         | NR       | 15<sup>30-d</sup> | 15<sup>30-d</sup> | 36%            | 15%            | NR         | NR         |
| Vargas wi [48]    | 1995 | 35    | 11   | NR         | NR       | NR         | NR       | 58%            | 1-YS LT       | 81%        | 40         |
| Tan wi [49]       | 1995 | 12    | 15   | NR         | NR       | NR         | NR       | 33<sup>3-YS</sup> | 33<sup>3-YS</sup> | 63%        | 45         |
| Michel wi [50]    | 1997 | 102   | 113  | NR         | NR       | 15<sup>30-d</sup> | 15<sup>30-d</sup> | 31%            | 32%            | NR         | NR         |
| Philosophewi [51] | 1998 | 35    | 85   | NR         | NR       | 4.6<sup>30-d</sup> | 6.2<sup>30-d</sup> | 41%            | 69%            | NR         | NR         |
| Otto wi [54]      | 1998 | 52    | 50   | NR         | NR       | 21<sup>30-d</sup> | 8.0<sup>30-d</sup> | 37%            | 44%            | 21         | 8.0        |
| Weimann NR [55]   | 1999 | 32    | 31   | NR         | NR       | 13<sup>30-d</sup> | 10<sup>30-d</sup> | 34%            | 63%            | 19         | 0          |
| Yamamoto wi [25]  | 1999 | 294   | 270  | NR         | NR       | 1.4<sup>30-d</sup> | 7.8<sup>30-d</sup> | 47%            | 54%            | NR         | NR         |
| Llovet [19]       | 1999 | 77    | 87   | NR         | NR       | 3.9<sup>30-d</sup> | 2.3<sup>30-d</sup> | 51%            | 69%            | 57         | 7.4        |
| Figueiras wi [56] | 2000 | 35    | 85   | NR         | NR       | 6.7<sup>NR</sup> | NR       | 51%            | 60%            | 65         | 7.0        |
| De Carli wi [57]  | 2001 | 131   | 91   | NR         | NR       | 4.5<sup>30-d</sup> | 18<sup>90-d</sup> | 38%            | 65%            | 62         | 7.0        |
| Shabahangi [58]   | 2002 | 44    | 65   | NR         | NR       | 7.0<sup>NR</sup> | 7.0<sup>NR</sup> | 57%            | 66%            | 3-YS NR NR  |
| Bigourdan wi [59] | 2003 | 20    | 17   | 30<sup>30-d</sup> | 47<sup>30-d</sup> | 5.0<sup>30-d</sup> | 0<sup>30-d</sup> | 36%            | 71%            | 30         | 18         |
| Pierie NR [60]    | 2005 | 81    | 33***| NR         | NR       | 20<sup>30-d</sup> | 9.6<sup>30-d</sup> | 10%            | 19%            | NR         | NR         |
| Margarit wi [61]  | 2005 | 37    | 36   | NR         | NR       | 2.7<sup>30-d</sup> | 5.6<sup>30-d</sup> | 78%            | 50%            | 59         | 11         |
| Poon wi [62]      | 2007 | 204   | 43   | 35<sup>30-d</sup> | 44<sup>30-d</sup> | 3.4<sup>H</sup> | 0<sup>H</sup> | 68%            | 81%            | NR         | NR         |
| Cillo wi [63]     | 2007 | 131   | 40   | NR         | NR       | 5.3<sup>30-d</sup> | 7.5<sup>30-d</sup> | 31%            | 63%            | 53         | 5.0        |
| Del Gaudio wi [22] | 2008 | 80    | 293  | NR         | 79<sup>NR</sup> | 0<sup>NR</sup> | 5.0<sup>NR</sup> | 66%            | 58%            | 59         | 46         |
| Bellavance wi [64] | 2008 | 245   | 134  | 49<sup>30-d</sup> | 65<sup>30-d</sup> | 1.6<sup>30-d</sup> | 1.5<sup>30-d</sup> | 46%            | 66%            | 50         | 14         |
| Sotiropoulo wi [65] | 2009 | 61    | 60   | 38<sup>30-d</sup> | 38<sup>30-d</sup> | 23<sup>30-d</sup> | 8.0<sup>30-d</sup> | 23%            | 59%            | NR         | NR         |
| Zhou wi [66]      | 2010 | 1018  | 89   | NR         | NR       | 0.69<sup>NR</sup> | 4.5<sup>NR</sup> | 70%            | 89%            | NR         | NR         |

Abbreviations: RSX: resection; LT: liver transplantation; YS: year-survival; Mb: morbidity; Mt: mortality; Rec: recurrence.

**RSX and LT combined.

**Cirrhotic and noncirrhotic livers combined.

***33 wait-list patients (22 transplanted patients).

wiAll patients within Milan criteria.

/oSome patients within and some outside of Milan criteria.

NRMilan criteria not reported.

HHospital mortality (during same admission for same treatment).

Occur from inappropriate stratification based on stage of disease. Staging of HCC is in fact plagued by an inordinate number of staging systems. At the time of the recent American Hepato-Pancreato-Biliary Association/American Joint Commission on Cancer (AHPBA/AJCC) Consensus Conference on Multidisciplinary Treatment of HCC staging [7], there were 18 different staging or scoring systems—or versions thereof—in use around the world. A major reason that HCC staging is difficult is that, to a greater extent in HCC compared with other cancers, prognosis after surgical treatment of HCC depends not only on tumor factors, such as size, number, and invasiveness (as are used in AJCC staging), but also on factors related to patient comorbidities, performance status, and quality-of-life scores, factors related to liver disease, factors related to etiology of disease (e.g., alcohol versus hepatitis B versus hepatitis C), and interactions between these groups of factors [7]. Whatever the reason—selection bias or a true finding—the many available data suggest that the rates of long-term survival and recurrence after transplantation are superior to those observed following resection (Table 1).

In the early history of liver transplantation from the 1960s through the 1980s, transplantation was considered to be indicated for primary liver tumors not resectable by subtotal techniques [8–10]. However, recurrence rates as high as 82% [10] and single-digit 5-year survival rates [9] were disappointing. Subsequently, the observation [10–12] that small HCC identified on pathologic evaluation
of explanted livers transplanted for other indications were associated with low recurrence rates and long-term survival led to the development of the above-mentioned Milan criteria. Patients meeting these criteria in the original study by Mazzaferro et al. had overall and recurrence-free 4-years survival rates of 85% and 92% percent, respectively, following liver transplantation [6]. These results have since been corroborated in subsequent series published in the 2000s, with recurrence rates as low as 2% and 5-year survival rates as high as 89% following liver transplantation for HCC (Table 1).

4. Advantages of Resection

4.1. Easier. Unfortunately, the high 5-year survival rates and the low recurrence rates possible following liver transplantation are available only to those patients waiting for a graft who actually get one, whereas resection is more easily and immediately available to all acceptable-risk patients. In fact, the national median waiting times based on Organ Procurement and Transplantation Network (OPTN) data as of December 2010 range from 140 days for American Indians to 651 days for Hispanics [13], during which time patients may drop out because of tumor or comorbid progression, death, or other reasons. Depending on the time period, type of analysis, and dropout criteria [14], the 1-year dropout rate for patients with HCC awaiting liver transplantation ranges from 12% to 38% [14–18]. When these dropouts were considered in one of the first intention-to-treat analyses [19], the 2-year survival decreased significantly from 84% to 54%. Although subsequent intention-to-treat studies accounting for dropouts have reported good 4-year survival rates of approximately 60% following transplantation for HCC [17, 18], other factors are not accounted for, such as socioeconomic barriers that may prevent many patients ever from being listed for transplantation. Resection, by contrast, is available more easily, widely, and immediately to all patients who can tolerate the operation. Not only is resection a modality that is easier for patients to obtain, but it is easier for surgeons to perform, since it almost never requires venovenous bypass and does not require transplantation fellowship training, which some but not all hepatobiliary fellowships include. Resection, however, should not necessarily be viewed as a mutually exclusive modality but rather a complementary one, since its easy availability makes it effective not only in achieving long-term survival, but also effective for use as both a selection tool for transplantation, and a bridge to transplantation, as discussed below.

4.2. Effective. Given the absence of randomized controlled trials comparing resection and transplantation, estimates of their relative effectiveness must at least be based on similar patient populations to avoid selection bias. To that end, several groups have studied transplantation-eligible patients, that is, patients meeting the Milan criteria for transplantation, who underwent resection, not transplantation. Such transplantation-eligible patients undergoing resection had 5-year survival rates of 70% at two large hepatobiliary centers [20, 21], a rate comparable with some of the best reported following liver transplantation (Table 1). In a more recent intention-to-treat analysis of 80 transplantation-eligible HCC patients who underwent resection compared to 293 patients listed for transplantation, 5-year survival was similar (66% and 58%, resp.) [22]. This is consistent with the observation in a 2009 review of nearly 60 series of resection and/or transplantation that the weighted mean of reported 5-year survival rates is similar for resection and transplantation: 48% and 52%, respectively [23].

Not only is resection effective at producing a 5-year survival comparable to that of transplantation, but in cases of recurrence—which is uniformly higher following resection compared with transplantation (Table 1)—transplantation remains an option. This strategy of salvage liver transplantation (SLT) has the advantage of limiting the impact on the available pool of donors since the majority of transplantation-eligible patients undergoing resection without recurrence would not draw from this valuable and limited resource of liver grafts.

Salvage transplantation was formally proposed first in 1998 by Llovet et al. [24], although several other authors were also studying this strategy around the same time [25–27]. Two simultaneously published articles in Annals of Surgery, by Adam et al. [28] and Belghiti et al. [29], popularized the approach in 2003, reporting disparate conclusions. Adam et al. compared 17 patients who underwent SLT for recurrence of HCC after resection with 195 patients following primary liver transplantation (PLT) and found significantly higher mortality (23.5%), shorter survival, and more recurrence in SLT patients compared to PLT [28]. Belghiti et al., by contrast, included an intention-to-treat analysis and found similar rates of complications, 5-year survival, and recurrence [29]. These latter results of Belghiti et al. have more recently been corroborated by other groups. Del Gaudio et al. reviewed the results of 227 cirrhotic patients with transplantation-eligible HCC: 80 who underwent liver resection and 147 liver transplantation [22]. Among the liver-resection patients, 49% recurred and of those who recurred, 69% were within the Milan criteria for transplantation, of whom 10 underwent SLT. Compared with patients who underwent primary transplantation, SLT patients had similar rates of complications, 5-year survival, and recurrence [22]. Cherqui et al. studied 67 transplantation-eligible patients who underwent resection and found that of 36 (54%) patients with a recurrence, 16 (44%) who underwent SLT had a 5-year survival rate of 70% [30].

De principe SLT is another strategy to minimize use of scarce liver grafts by using resection as a tool to select patients who, based on pathologic evaluation of the specimen, have risk factors for recurrence (e.g., microscopic vascular invasion, the presence of previously unrecognized small satellite nodules). The Barcelona Clinic Liver Cancer group has employed this strategy, finding it to be an effective way to improve the outcome of resected patients [31]. Of 17 patients who were candidates for either resection or transplantation, but who underwent resection, 8 were deemed high-risk and therefore offered immediate transplantation. Of 6 who agreed to de principe SLT, 5 were transplanted and although 4 of these 5 had no pretransplantation evidence of HCC,
4 indeed were found to harbor unrecognized HCC in the explanted liver but were free of disease at a median follow-up of 45 months [31].

The use of resection as an effective tool to select patients for de principe SLT was corroborated by Scotton et al. who studied 93 patients who underwent curative-intent surgery for HCC, primary resection in 20 (all 20 of whom had well-compensated cirrhosis with a Model for End-Stage Liver Disease score of 8) and primary transplantation in 73 [32]. Six of the 20 resection patients underwent de principe SLT and 14 underwent SLT for actual recurrence. Not all 20 were within the Milan criteria at resection: Twelve (9 SL T and 14 underwent SLT for actual recurrence. Not all 20

4.3. Safer. Not only is liver resection easier and as effective as primary transplantation, it is also likely safer. Although this claim is made with the understanding that there are no randomized controlled trials to support it, it is intuitively true, given that all transplantations are major and complex operations, even when done for small tumors. A liver resection for a small tumor, in a liver with well-compensated cirrhosis, however, is in general a lower-risk procedure, and can sometimes even be performed laparoscopically. In fact, a series of 163 liver resections for HCC (74% on cirrhosis) performed at 3 large European centers recently reported median operative time of 180 min, blood loss of 250 mL, and tumor size 3.6 cm, with a mean length of stay of 7 days [33]. A recent review of nearly 60 series of either transplantation, resection, or direct comparisons of the two modalities in the treatment of early HCC found that the weighted means of postoperative morbidity rates was nearly identical (44% for resection and 45% for transplantation), but mortality following transplantation was 60% higher than following resection (8% and 5%, resp.) [23].

While both resection and transplantation may be performed safely, resection has the additional advantage of delaying need for and risks associated with immunosuppression. These risks include toxicities (especially nephrotoxicity), infectious complications, and posttransplantation de novo neoplasms, among others. Nephrotoxicity is common after liver transplantation and adversely affects graft and patient survival [34]. Immunosuppression-related posttransplantation infection is a significant problem that is entirely avoided with resection. In a series of 1000 liver transplantations treated with tacrolimus immunosuppression, posttransplantation infection was the most common cause of death (34% of 360 deaths) [35]. In cases of HCV-related HCC, reinfection of a new liver graft following transplantation is universal and serum HCV levels have been shown to increase 4- to 100-fold during treatment for acute rejection [36]. Posttransplantation neoplasms occur at a rate several-fold higher than age- and sex-matched individuals [37], and include skin cancers and lymphoma (up to 10-fold risk) [37–40], myelodysplastic syndrome [41], and other extrahepatic cancers, such as those of the head and neck, lung, and gastrointestinal tract [42].

4.4. Simpler. In addition to being safer, easier, and comparably effective relative to transplantation, resection has the advantage of simpler preoperative and postoperative management. Any patient being evaluated for either modality requires extensive workup regarding HCC and comorbid factors, but transplantation requires in addition an extensive preoperative process that includes myriad wait-list issues, psychosocial evaluation of recipients and live donors, and the universal emergent nature of the operations.

Bryce et al. [43] have studied the impact of sociodemographic factors on access to transplantation services and identified six stages that a patient must pass through prior to transplantation: disease occurrence, disease progression, disease diagnosis, referral for transplantation, listing for transplantation, and finally organ transplantation. Reasons preventing patients from completing all of these stages are numerous and include medical unsuitability for a transplantation, refusal of treatment, disparities/bias, and death. Using Pennsylvania state databases to collect sociodemographic and socioeconomic information, they linked data to records from five centers responsible for 95% of liver transplantations in Pennsylvania, and found that patients were significantly less likely to undergo evaluation, wait-listing, and transplantation if they were women, African American, or lacked commercial insurance [43]. Furthermore, these differences were greater during the early stages of the preoperative process (referral and listing) than for the final transplantation stage, where national oversight and review occur [43].

Postoperative management is similarly complex and requires a higher level of dedication, compliance, and investment of time, energy, and attention on the part of the patient than is possible for many patients, especially those of lower socioeconomic status. Noncompliance with immunosuppressive regimens and follow-up schedules has obvious risk for graft rejection and systemic toxicity and is more common in patients of low socioeconomic status [44]. Furthermore, for reasons that are not well defined, low-socioeconomic patients may also have worse survival following transplantation for HCC. In a study of 4735 patients identified in the OPTN database, although the survival of all patients with HCC improved over time regardless of racial, ethnic, and income groups, African American and low-income individuals had significantly poorer long-term survival compared to other socioeconomic groups [45].

5. Conclusion

Although liver transplantation provides the best recurrence-free survival and the best chance for a cure of HCC on well-compensated cirrhosis, due to the complete removal of all hepatic HCC disease and all oncogenic cirrhotic liver, the current (and likely future) shortage of available grafts,
and the increased risks and complexities associated with the pre-, intra-, and postoperative course of liver transplantation counterbalance this advantage of transplantation. Furthermore, in cases of recurrence (or high risk thereof)—the one clear disadvantage of resection—transplantation remains a safe option. Taken together, these arguments suggest that resection is easier, safer, simpler, and as effective compared with transplantation and therefore is the optimal first choice for patients with early HCC on well-compensated cirrhosis.

References

[1] J. D. Yang and L. R. Roberts, “Hepatocellular carcinoma: a global view,” Nature Reviews Gastroenterology and Hepatology, vol. 7, pp. 448–458, 2010.
[2] H. B. El-Serag and A. C. Mason, “Rising incidence of hepatocellular carcinoma in the United States,” New England Journal of Medicine, vol. 340, no. 10, pp. 745–750, 1999.
[3] H. Nordenstedt, D. L. White, and H. B. El-Serag, “The changing pattern of epidemiology in hepatocellular carcinoma,” Digestive and Liver Disease, vol. 42, no. 3, pp. 206–214, 2010.
[4] H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007.
[5] H. Bismuth, L. Chiche, R. Adam, D. Castaing, T. Diamond, and A. Dennison, “Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients,” Annals of Surgery, vol. 218, no. 2, pp. 145–151, 1993.
[6] V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996.
[7] J. N. Vaught, E. Dixon, E. K. Abdalla et al., “ Pretreatment assessment of hepatocellular carcinoma: expert consensus statement,” HPB, vol. 12, no. 5, pp. 289–299, 2010.
[8] R. Pichlmayr, A. Weimann, and B. Ringe, “Indications for liver transplantation in hepatobiliary malignancy,” Hepatology, vol. 20, no. 1, part 2, pp. 355–405, 1994.
[9] R. Pichlmayr, “Is there a place for liver grafting for malignancy?” Transplantation Proceedings, vol. 20, no. 1, pp. 478–482, 1988.
[10] S. Iwatsuki, R. D. Gordon, B. W. Shaw Jr., and T. E. Starzl, “Role of liver transplantation in cancer therapy,” Annals of Surgery, vol. 202, no. 4, pp. 401–407, 1985.
[11] R. L. Jenkins, C. Wright Pinson, and M. D. Stone, “Experience with transplantation in the treatment of liver cancer,” Cancer Chemotherapy and Pharmacology, vol. 23, pp. S104–S109, 1989.
[12] S. Iwatsuki, T. E. Starzl, S. Todo et al., “Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report,” Transplantation Proceedings, vol. 20, no. 1, supplement 1, pp. 498–504, 1988.
[13] OPTN, “Organ Procurement and Transplantation Network,” December 2010, http://optn.transplant.hrsa.gov/.
[14] A. Vitale, P. Boccagni, A. Brolese et al., “Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?” Transplantation Proceedings, vol. 41, no. 4, pp. 1264–1267, 2009.
[15] F. Y. Yao, N. M. Bass, N. L. Ascher, and J. P. Roberts, “Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy,” Liver Transplantation, vol. 10, no. 5, pp. 621–630, 2004.
[16] F. Y. Yao, N. M. Bass, B. Nikolai et al., “Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and Dropout from the waiting list,” Liver Transplantation, vol. 8, no. 10, pp. 873–883, 2002.
[17] S. J. Pelletier, S. Fu, V. Thyagarajan et al., “An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data,” Liver Transplantation, vol. 15, no. 8, pp. 859–868, 2009.
[18] M. E. Facciuto, C. Rochon, M. Pandey et al., “Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and without Milan criteria,” HPB, vol. 11, no. 5, pp. 398–404, 2009.
[19] J. M. Llovet, J. Fuster, and J. Bruix, “Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation,” Hepatology, vol. 30, no. 6, pp. 1434–1440, 1999.
[20] C. H. Cha, L. Rao, Y. Fong et al., “Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation,” Annals of Surgery, vol. 238, no. 3, pp. 315–323, 2003.
[21] R. T. P. Poon, S. T. Fan, C. M. Lo, C. L. Liu, and J. Wong, “Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation,” Annals of Surgery, vol. 235, no. 3, pp. 373–382, 2002.
[22] M. Del Gaudio, G. Ercolani, M. Ravaiol et al., “Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience,” American Journal of Transplantation, vol. 8, no. 6, pp. 1177–1185, 2008.
[23] S. C. Cunningham, S. Tsai, H. P. Marques et al., “Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis,” Annals of Surgical Oncology, vol. 16, no. 7, pp. 1820–1831, 2009.
[24] J. M. Llovet, J. Bruix, J. Fuster et al., “Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power,” Hepatology, vol. 27, no. 6, pp. 1572–1577, 1998.
[25] J. Yamamoto, S. Iwatsuki, T. Kosuge et al., “Should hepatomas be treated with hepatic resection or transplantation?” Cancer, vol. 86, no. 7, pp. 1151–1158, 1999.
[26] P. E. Majno, F. P. Sarasin, G. Mentha, and A. Hadengue, “Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis,” Hepatology, vol. 31, no. 4, pp. 899–906, 2000.
[27] H. Bismuth, P. E. Majno, and R. Adam, “Liver transplantation for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 19, no. 3, pp. 311–321, 1999.
[28] R. Adam, D. Azoulay, D. Castaing et al., “Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?” Annals of Surgery, vol. 238, no. 4, pp. 508–519, 2003.
[29] J. Belgïhi, A. Cortes, E. K. Abdalla et al., “Resection prior to liver transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 238, no. 6, pp. 885–893, 2003.
[30] D. Cherqui, A. Laurent, N. Mocellin et al., “Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation,” Annals of Surgery, vol. 250, no. 5, pp. 738–745, 2009.
[31] M. Sala, J. Fuster, J. M. Llovet et al., “High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and Dropout from the waiting list,” Liver Transplantation, vol. 8, no. 10, pp. 873–883, 2002.
carcinoma: an indication for salvage liver transplantation,” *Liver Transplantation*, vol. 10, no. 10, pp. 1294–1300, 2004.

[32] O. Scatton, S. Zalinski, B. Terris et al., “Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation,” *Liver Transplantation*, vol. 14, no. 6, pp. 779–788, 2008.

[33] I. Dagher, G. Belli, C. Fantini et al., “Laparoscopic hepatectomy for hepatocellular Carcinoma: a European experience,” *Journal of the American College of Surgeons*, vol. 211, no. 1, pp. 16–23, 2010.

[34] R. Bahirwani and K. R. Reddy, “Outcomes after liver transplantation: chronic kidney disease,” *Liver Transplantation*, vol. 15, pp. S70–S74, 2009.

[35] A. Jain, J. Reyes, R. Kashyap et al., “What have we learned about primary liver transplantation under tacrolimus immunosuppression?—Long-term follow-up of the first 1000 patients,” *Annals of Surgery*, vol. 230, no. 3, pp. 441–449, 1999.

[36] E. J. Gane, N. V. Naoumov, K. P. Qian et al., “A longitudinal analysis of hepatitis C virus replication following liver transplantation,” *Gastroenterology*, vol. 110, no. 1, pp. 167–177, 1996.

[37] J. I. Herrero, “De novo malignancies following liver transplantation: impact and recommendations,” *Liver Transplantation*, vol. 15, supplement 2, pp. S90–S94, 2009.

[38] K. Kataoka, S. Seo, Y. Sugawara et al., “Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature,” *Leukemia and Lymphoma*, vol. 51, no. 8, pp. 1494–1501, 2010.

[39] D. Marino, P. Burra, P. Boccagni et al., “Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience,” *Anticancer Research*, vol. 30, no. 6, pp. 2383–2391, 2010.

[40] B. Geramizadeh, S.-A. Malek-Hosseini, A. Bahador et al., “Post-transplantation lymphoproliferative disorder after liver transplantation: report of 5 cases among more than 550 liver transplants in Iran,” *Archives of Iranian Medicine*, vol. 13, no. 5, pp. 417–419, 2010.

[41] R. Potru, J. Ahn, H. Fung, and S. M. Cohen, “A case of myelodysplastic syndrome in a liver transplant patient,” *Transplantation Proceedings*, vol. 41, no. 9, pp. 3947–3948, 2009.

[42] C. Vanlemmens, V. Di Martino, C. Milan et al., “Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis. A Randomized Trial,” *Annals of Internal Medicine*, vol. 150, no. 3, pp. 153–161, 2009.

[43] C. L. Bryce, D. C. Angus, R. M. Arnold et al., “Sociodemographic differences in early access to liver transplantation services,” *American Journal of Transplantation*, vol. 9, no. 9, pp. 2092–2101, 2009.

[44] R. T. Schweizer, M. Rovelli, D. Palmeri, E. Vossler, D. Hull, and S. Bartsch, “Noncompliance in organ transplant recipients,” *Transplantation*, vol. 49, no. 2, pp. 374–377, 1990.

[45] A. Artinyan, B. Mailey, N. Sanchez-Luege et al., “Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States,” *Cancer*, vol. 116, no. 5, pp. 1367–1377, 2010.

[46] S. Iwatsuki, T. E. Starzl, D. G. Sheehan et al., “Hepatic resection versus transplantation for hepatocellular carcinoma,” *Annals of Surgery*, vol. 214, no. 3, pp. 221–229, 1991.

[47] B. Ringé, R. Pichlmayr, C. Wittekind, and G. Tusch, “Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients,” *World Journal of Surgery*, vol. 15, no. 2, pp. 270–285, 1991.

[48] V. Vargas, L. Castells, J. Balsells et al., “Hepatic resection or orthotopic liver transplant in cirrhotic patients with small hepatocellular carcinoma,” *Transplantation Proceedings*, vol. 27, no. 1, pp. 1243–1244, 1995.

[49] K. C. Tan, M. Rela, S. D. Ryder et al., “Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis,” *British Journal of Surgery*, vol. 82, no. 2, pp. 253–256, 1995.

[50] J. Michel, B. Suc, F. Montpeyroux et al., “Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis,” *Journal of Hepatology*, vol. 26, no. 6, pp. 1274–1280, 1997.

[51] B. Philosophe, P. D. Greig, A. W. Hemming et al., “Surgical management of hepatocellular carcinoma: resection or transplantation?” *Journal of Gastrointestinal Surgery*, vol. 2, no. 1, pp. 21–27, 1998.

[52] G. Colella, L. de Carlis, G. F. Rondinini et al., “Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation?” *Transplantation Proceedings*, vol. 29, no. 1-2, pp. 492–494, 1997.

[53] A. Mazzotti, G. L. Grazi, and A. Cavallari, “Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience,” *Hepato-Gastroenterology*, vol. 45, supplement 3, pp. 1281–1287, 1998.

[54] G. Otto, U. Heuschen, W. J. Hofmann, G. Krumm, U. Hinze, and C. Herfarth, “Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis,” *Annals of Surgery*, vol. 227, no. 3, pp. 424–432, 1998.

[55] A. Weimann, H. J. Schlitt, K. J. Oldhafer, S. Hoberg, G. Tusch, and R. Raab, “Is liver transplantation superior to resection in early stage hepatocellular carcinoma?” *Transplantation Proceedings*, vol. 31, no. 1-2, pp. 500–501, 1999.

[56] J. Figueras, E. Jaurrieta, C. Valls et al., “Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: on indicated treatment strategy,” *Journal of the American College of Surgeons*, vol. 190, no. 5, pp. 580–587, 2000.

[57] L. de Carlis, A. Giaconomi, V. Pirotta et al., “Treatment of HCC: the role of liver resection in the era of transplantation,” *Transplantation Proceedings*, vol. 33, no. 1-2, pp. 1453–1456, 2001.

[58] M. Shabahang, D. Franceschi, N. Yamashiki et al., “Comparison of hepatic resection and hepatocellular carcinoma: resection or transplantation for hepatocellular carcinoma among cirrhotic patients,” *Annals of Surgical Oncology*, vol. 9, no. 9, pp. 881–886, 2002.

[59] J. M. Bigourdan, D. Ja Eck, N. Meyer et al., “Small hepatocellular carcinoma in child A cirrhotic patients: hepatic resection versus transplantation,” *Liver Transplantation*, vol. 9, no. 5, pp. 513–520, 2003.

[60] J. P. E. N. Pierie, A. Muzikansky, K. K. Tanabe, and M. J. Ott, “The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma,” *Annals of Surgical Oncology*, vol. 12, no. 7, pp. 552–560, 2005.

[61] C. Margarit, A. Escartin, L. Castells, V. Vargas, E. Allende, and I. Bilbao, “Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation,” *Liver Transplantation*, vol. 11, no. 10, pp. 1242–1251, 2005.

[62] R. T. Poon, S. T. Fan, C. M. Lo, C. L. Liu, and J. Wong, “Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival,” *Annals of Surgery*, vol. 245, no. 1, pp. 51–58, 2007.

[63] U. Cillo, A. Vitale, A. Brolo et al., “Partial hepectomy as first-line treatment for patients with hepatocellular
carcinoma,” *Journal of Surgical Oncology*, vol. 95, no. 3, pp. 213–220, 2007.

[64] E. C. Bellavance, K. M. Lumpkins, G. Mentha et al., “Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?” *Journal of Gastrointestinal Surgery*, vol. 12, no. 10, pp. 1699–1708, 2008.

[65] G. C. Sotiropoulos, N. Dühe, G. Sgourakis et al., “Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?” *Digestive Diseases and Sciences*, vol. 54, no. 10, pp. 2264–2273, 2009.

[66] J. Zhou, Z. Wang, S. J. Qiu et al., “Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation,” *Journal of Cancer Research and Clinical Oncology*, vol. 136, no. 9, pp. 1453–1460, 2010.